MARKET

GPCR

GPCR

Structure Therapeutics Inc ADR
NASDAQ
54.13
+0.60
+1.12%
Pre Market: 55.44 +1.31 +2.42% 07:07 08/20 EDT
OPEN
54.30
PREV CLOSE
53.53
HIGH
55.35
LOW
52.40
VOLUME
125
TURNOVER
0
52 WEEK HIGH
94.90
52 WEEK LOW
18.26
MARKET CAP
3.86B
P/E (TTM)
-17.3895
1D
5D
1M
3M
1Y
5Y
1D
J.P. Morgan Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 3d ago
Weekly Report: what happened at GPCR last week (0810-0814)?
Weekly Report · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 08/10 12:20
Guggenheim Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 08/10 11:35
Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
TipRanks · 08/10 11:00
Weekly Report: what happened at GPCR last week (0803-0807)?
Weekly Report · 08/10 09:08
SA Asks: What's the outlook for Big Pharma M&A?
Seeking Alpha · 08/08 19:28
Advancing Oral GLP‑1 and Amylin Pipeline Supports GPCR Buy Rating with Maintained $70 Price Target
TipRanks · 08/07 20:28
More
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Webull offers Structure Therapeutics Inc (ADR) stock information, including NASDAQ: GPCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GPCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GPCR stock methods without spending real money on the virtual paper trading platform.